As Health Reform Takes Final Shape, Pharma Provisions Still In Play
Even as news that a breakthrough on one of the major issues separating the House and Senate health care reform bills - taxing high-cost health care plans -emerged near the end of the week of Jan. 11, issues of keen interest for biopharma stakeholders remained unsettled
You may also be interested in...
As health care reform approaches a House-Senate conference, there is speculation that pharma will commit more money in order to keep the door closed on broader rebates.
Pharmacy benefit management companies are objecting to an idea that an annual fee on PBMs could be levied to go towards eliminating the Medicare Part D gap in drug coverage.